I am a breastfeeding mother and i want to know if it is safe to use IL-1RA? Is IL-1RA safe for nursing mother and child? Does IL-1RA extracts into breast milk? Does IL-1RA has any long term or short term side effects on infants? Can IL-1RA influence milk supply or can IL-1RA decrease milk supply in lactating mothers?
- DrLact safety Score for IL-1RA is 3 out of 8 which is considered Low Risk as per our analyses.
- A safety Score of 3 indicates that usage of IL-1RA may cause some minor side effects in breastfed baby.
- Our study of different scientific research indicates that IL-1RA may cause moderate to no side effects in lactating mother.
- Most of scientific studies and research papers declaring usage of IL-1RA low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- While using IL-1RA We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
It is indicated for treatment of rheumatoid arthritis in combination with methrotexate (the latter is contraindicated during lactation). A 153-aminoacid containing polypeptide with a large molecular weight. Excretion into breast milk is unlikely and subsequent oral absorption would be nil especially after one week post partum. No adverse effect in breastfed infants has been reported.
Anainra is the pharmaceutical name for recombinant human interleukin-1 receptor antagonist (IL-1Ra). IL-1Ra is a normal component of human milk where it may play a role as an anti-inflammatory agent. No data exist on the excretion of IL-1RA into breastmilk after exogenous administration. Several infants have been breastfed during maternal IL-1RA therapy with no obvious adverse effects. If IL-1RA is required by the mother, it is not a reason to discontinue breastfeeding.[1]
A woman was receiving IL-1RA 100 mg daily for adult-onset Still's disease during pregnancy and lactation. Her breastfed (extent not stated) infant gained wight and appeared to have normal psychomotor development during an unspecified follow-up period.[4] Among a cohort of 18 women with term pregnancies treated with IL-1RA for cryopyrin-associated periodic syndromes during pregnancy, 3 of the women breastfed their infants (extent not stated) for periods of <1 month, 3 months and 1 year. No adverse neonatal outcomes were reported.[5] In an international multicenter study of mothers exposed to interleukin-1 receptor antagonists, 10 babies were breastfed (extent not stated) by mothers receiving IL-1RA for up to 10 months. No infections or developmental abnormalities were reported.[6] Three of the cases had been reported previously in reference[5]. Of 5 women who took IL-1RA during pregnancy, two breastfed their infants while continuing to receive IL-1RA 100 mg daily. No serious infections were reported and development was normal.[7]
Disclaimer:
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.